Prescription of vitamin D was associated with a lower incidence of hip fractures.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 08 2023
09 08 2023
Historique:
received:
08
10
2022
accepted:
07
08
2023
medline:
11
8
2023
pubmed:
10
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Patients with osteoporosis are prone to fragility fractures. Evidence of the effects of active forms of vitamin D on hip fracture prevention is insufficient. We examined the association between vitamin D prescription and incidence of new fractures using the data of osteoporotic patients from the nationwide health insurance claims database of Japan. The follow-up period was 3 years after entry. The untreated patients were never prescribed vitamin D during follow-up (n = 422,454), and the treated patients had a vitamin D medication possession ratio of ≥ 0.5 at all time points (n = 169,774). Propensity score matching was implemented on these groups, yielding 105,041 pairs, and subsequently, the control and treatment groups were established and analyzed. The incidence of new fractures was significantly lower in the treatment group compared with the control group (6.25% vs. 5.69%, hazard ratio 0.936 [95% confidence interval 0.904-0.970], p < 0.001*). By site, hip fractures significantly decreased (0.89% vs. 0.42%, p < 0.001), but not vertebral and radial fractures. Subgroup analysis by vitamin D type showed a significantly lower incidence of total fractures only in alfacalcidol (hazard ratio 0.676 [95% confidence interval 0.628-0.728], p < 0.001*). The results suggest that vitamin D prescription was associated with a reduced incidence of hip fractures.
Identifiants
pubmed: 37558795
doi: 10.1038/s41598-023-40259-6
pii: 10.1038/s41598-023-40259-6
pmc: PMC10412563
doi:
Substances chimiques
Vitamin D
1406-16-2
Bone Density Conservation Agents
0
Vitamins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12889Informations de copyright
© 2023. Springer Nature Limited.
Références
Ann Surg. 2013 Apr;257(4):640-6
pubmed: 23023204
J Bone Miner Metab. 2022 Jul;40(4):541-553
pubmed: 35639176
J Bone Miner Res. 2006 Jun;21(6):809-16
pubmed: 16753011
J Clin Endocrinol Metab. 2022 Feb 17;107(3):882-898
pubmed: 34687206
J Am Geriatr Soc. 2002 Oct;50(10):1644-50
pubmed: 12366617
Osteoporos Int. 2000;11(10):822-31
pubmed: 11199185
J Bone Miner Metab. 2013 Jul;31(4):417-22
pubmed: 23575909
J Orthop Surg Res. 2021 Nov 13;16(1):669
pubmed: 34774085
EClinicalMedicine. 2020 Jun 15;23:100411
pubmed: 32566923
BMJ. 2009 Oct 01;339:b3692
pubmed: 19797342
J Bone Miner Metab. 2013 Mar;31(2):183-9
pubmed: 23129180
Endocr J. 1996 Apr;43(2):211-20
pubmed: 9026268
Osteoporos Int. 2019 Jan;30(1):79-92
pubmed: 30456571
Calcif Tissue Int. 2005 Mar;76(3):176-86
pubmed: 15692726
JPEN J Parenter Enteral Nutr. 2021 Nov;45(8):1703-1713
pubmed: 33483948
Bone. 2011 Oct;49(4):605-12
pubmed: 21784190
Lancet. 2022 Mar 12;399(10329):1080-1092
pubmed: 35279261
J Clin Endocrinol Metab. 2001 Aug;86(8):3618-28
pubmed: 11502787
Menopause. 2016 Mar;23(3):267-74
pubmed: 26554884
Arch Osteoporos. 2021 Jan 16;16(1):15
pubmed: 33452949
Arch Osteoporos. 2018 Oct 23;13(1):114
pubmed: 30353299
Bone. 2002 Apr;30(4):582-8
pubmed: 11934649
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1228-1240
pubmed: 31225722
J Bone Miner Metab. 2008;26(6):531-42
pubmed: 18979152
J Manag Care Spec Pharm. 2019 Oct;25(10):1073-1077
pubmed: 31556829
Calcif Tissue Int. 1999 Sep;65(3):183-7
pubmed: 10441647
J Bone Miner Res. 2013 Nov;28(11):2317-24
pubmed: 23616397
Arch Osteoporos. 2022 May 5;17(1):74
pubmed: 35513519